Novo Holdings, the investment holding company of Danish pharmaceutical group Novo Nordisk, is reportedly planning to sell up to 9.4 million shares, or approximately 5% of the share capital in Evotec SE (XTRA:EVT). Most recently, Novo Holdings was the second-largest shareholder in Hamburg-based Evotec with 14.9 million shares, or 8.4% of the shares. Novo had acquired a larger stake in Evotec, among other things, through a capital increase in 2017.